⭐️⭐️⭐️⭐️⭐️ "A total no brainer"

⭐️⭐️⭐️⭐️⭐️ "Love this, so easy."

Spots is the easy way to track your skin, mole and cancer changes.

Spots Global Cancer Trial Database for Metastatic Thyroid Cancer Therapy Optimization With 124I PET Dosimetry

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Metastatic Thyroid Cancer Therapy Optimization With 124I PET Dosimetry

Official Title: Personalized Therapy of Metastatic Thyroid Cancer: Biological Characterization and Optimization With 124I PET Dosimetry

Study ID: NCT05299437

Study Description

Brief Summary: Failure of conventional radioiodine therapy of metastatic differentiated thyroid cancer could be explained by: * a suboptimal therapeutic approach, based on the administration of empirically fixed amount of radioactivity * the presence of lesions with impaired iodine uptake, due to the expression of specific mutations The study aims to: * optimize therapy with pre-treatment 124-I blood and lesion dosimetry * collect genetic data to check if specific mutations and/or miRNA over-expression could be related to low iodine uptake or to radioresistance

Detailed Description: TRIAL DESIGN This is a one-stage, phase II, single-arm, bi-centric study. Enrollment centres are the Istituto Nazionale Tumori in Milan, and the Sacro Cuore Don Calabria Hospital in Negrar, close to Verona. Both centres are located in North Italy. 124-I is produced by cyclotron in Negrar Radiopharmacy unit, while high-activity 131-I therapy will be delivered in Milan. Patients with ascertained metastatic differentiated thyroid cancer are studied with FDG PET and CT. 124-I blood and lesion PET dosimetry is used to optimize the 131-I therapeutic activity. The same 124-I PET scans are repeated 6 months after therapy as response assessment. 124-I and 131-I administration are performed after hormon withdrawal. Primary tumour tissue and circulating miRNA will be analyzed to check the genetical features. According to 124-I dosimetric PET data published by Jentzen et al, good efficacy (Tumour Control Probability \> 80%) is obtained with absorbed dose \> 80 Gy to soft tissue metastases, and \> 650 Gy to bone metastases. Seen this difference, only soft tissue lesions are considered as target for the calculation of the complete response rate. However, for ethical reasons, therapeutic activity will be chosen in order to be effective both on soft tissue and bone lesions. Patients with too low predicted lesion absorbed dose even administering the Maximum Tolerable Activity (2 Gy to blood) will exit the protocol to receive the standard of care. PRIMARY END-POINT Evaluation of complete response (CR) rate on soft tissue metastases 6 months after treatment, or later. The best response will be considered. SECONDARY END-POINTS Assessment of: * acute toxicity rate and severity * the association among pre-treatment glucose metabolism, 124-I uptake and therapy response * the association among genetic mutations (BRAF V600E, TERT promoter, others) on thyroid cancer tissue, pre- and post-treatment miRNA expression, pre- and post-treatment glucose metabolism, iodine uptake, and 131-I therapy response SAMPLE SIZE AND POPULATION By considering a complete response (CR) rate in patients of soft tissue metastases after fixed activity approach as published by Klubo-Gwiezdzinska et al and by assuming an increment of 15% in CR rate after dosimetry-based administration, 46 evaluable patients will be required to test the above hypotheses.

Eligibility

Minimum Age: 18 Years

Eligible Ages: ADULT, OLDER_ADULT

Sex: ALL

Healthy Volunteers: No

Locations

Nuclear Medicine, Ospedale Sacro Cuore - Don Calabria, Negrar, Verona, Italy

Nuclear Medicine, Fondazione IRCCS Istituto Nazionale Tumori, Milan, , Italy

Contact Details

Name: Carlo Chiesa, PhD

Affiliation: Nuclear Medicine, Fondazione IRCCS Istituto Nazionale Tumori

Role: PRINCIPAL_INVESTIGATOR

Useful links and downloads for this trial

Clinicaltrials.gov

Google Search Results

Logo

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

spots app storespots app store

Join others from around the world: